SoftBank-backed biotech unicorn from Bay Area hits low end of IPO targets
October 11, 2019 at 10:13 AM EDT
The pricing of the San Francisco company's offering is seen as the latest sign that the market for IPOs is weakening at the end of what had been a very active year.
